Company research
Sio Gene Therapies Inc.
CIK 1636050Updated Nov 16, 2026
Securities
Historical securities (2)
SIOX · OTC · equity · closed Feb 7, 2024SIOX · OTC · equity · closed Feb 7, 2024Name history
Axovant Gene Therapies Ltd. · through Nov 13, 2020Axovant Sciences Ltd. · through Apr 18, 2019Roivant Neurosciences Ltd. · through Mar 24, 2015
SIOX price & chart
Historical security
This listing closed Feb 7, 2024. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 75,080,000Source | 135,147,000Source | 93,680,000Source | 122,706,000Source |
| Property, Plant and Equipment, NetUSD | 900,000Source | 478,000Source | 801,000Source | 1,278,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 63,729,000Source | 118,986,000Source | 80,752,000Source | 106,999,000Source |
| Assets, CurrentUSD | 71,736,000Source | 132,333,000Source | 85,430,000Source | 114,584,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,214,000Source | 7,348,000Source | 2,971,000Source | 5,859,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,444,000Source | 1,152,000Source | 1,532,000Source | — |
| Other Assets, NoncurrentUSD | — | 0Source | 46,000Source | 973,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 14,732,000Source | 11,780,000Source | 32,122,000Source | 66,493,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -862,956,000Source | -791,069,000Source | -758,644,000Source | -686,016,000Source |
| Stockholders' Equity Attributable to ParentUSD | 60,348,000Source | 123,367,000Source | 61,558,000Source | 56,213,000Source |
| Additional Paid in Capital, Common StockUSD | 922,966,000Source | 914,100,000Source | 820,257,000Source | 741,318,000Source |
| Liabilities and EquityUSD | 75,080,000Source | 135,147,000Source | 93,680,000Source | 122,706,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 13,002,000Source | 10,848,000Source | 32,043,000Source | 43,499,000Source |
| Operating Lease, Liability, CurrentUSD | 786,000Source | 311,000Source | 889,000Source | — |
| Accounts Payable, CurrentUSD | 3,984,000Source | 1,341,000Source | 4,412,000Source | 1,698,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,730,000Source | 932,000Source | 79,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 8,232,000Source | 9,196,000Source | 11,319,000Source | 20,619,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | — | 0Source | 15,423,000Source | 21,182,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 0Source | 22,994,000Source |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 268,000Source | 945,000Source | 1,477,000Source | 2,450,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,425,000Source | 4,492,000Source | 7,895,000Source | 16,429,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | -2,251,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -60,346,000Source | -46,589,000Source | -67,473,000Source | — |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 3,648,000Source | 12,386,000Source | -255,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,441,000Source | 73,621,000Source | 41,481,000Source | — |
| Repayments of Long-term DebtUSD | 0Source | 15,731,000Source | 29,563,000Source | 9,707,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -55,257,000Source | 39,418,000Source | -26,247,000Source | -47,338,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 64,913,000Source | 120,170,000Source | 80,752,000Source | 106,999,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 27,000Source | 465,000Source | 4,012,000Source | — |
| Income Taxes Paid, NetUSD | 5,000Source | 40,000Source | 562,000Source | 71,000Source |
| Additional Financial Items | ||||
| Gain (Loss) on InvestmentsUSD | 0Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -84,000Source | -19,000Source | -148,000Source |
| General and Administrative ExpenseUSD | 18,163,000Source | 17,294,000Source | 22,061,000Source | 39,466,000Source |
| Income Tax Expense (Benefit)USD | 259,000Source | -212,000Source | 438,000Source | 133,000Source |
| Net Income (Loss) Attributable to ParentUSD | -71,887,000Source | -32,425,000Source | -72,628,000Source | -129,065,000Source |
| Operating ExpensesUSD | 71,562,000Source | 42,197,000Source | 69,171,000Source | 127,018,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 1,600,000Source | 1,800,000Source | — |
| Other Nonoperating Income (Expense)USD | -39,000Source | 10,359,000Source | 1,358,000Source | 5,616,000Source |
| Proceeds from Contributed CapitalUSD | 0Source | 121,000Source | 148,000Source | 1,894,000Source |
| Proceeds from Issuance of Common StockUSD | 1,441,000Source | 89,231,000Source | 70,810,000Source | 94,549,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 0Source | 86,000Source | 335,000Source |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -71,628,000Source | -32,637,000Source | -72,190,000Source | -128,932,000Source |
| Other Nonoperating Income (Expense)USD | -39,000Source | 10,359,000Source | 1,358,000Source | 5,616,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -71,628,000Source | -32,637,000Source | -72,190,000Source | -128,932,000Source |
| Income Tax Expense (Benefit)USD | 259,000Source | -212,000Source | 438,000Source | 133,000Source |
| Net Income (Loss) Attributable to ParentUSD | -71,887,000Source | -32,425,000Source | -72,628,000Source | -129,065,000Source |
| Earnings Per Share, BasicUSD per share | -0.98Source | — | — | — |
| Earnings Per Share, DilutedUSD per share | -0.98Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 73,211,565Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 73,211,565Source | — | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 259,000Source | -212,000Source | 438,000Source | 133,000Source |
| Gain (Loss) on InvestmentsUSD | 0Source | — | — | — |
| General and Administrative ExpenseUSD | 18,163,000Source | 17,294,000Source | 22,061,000Source | 39,466,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -71,444,000Source | — | -5,216,000Source | -6,206,000Source |
| Interest ExpenseUSD | 27,000Source | 799,000Source | 4,377,000Source | 7,530,000Source |
| Operating ExpensesUSD | 71,562,000Source | 42,197,000Source | 69,171,000Source | 127,018,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 1,600,000Source | 1,800,000Source | — |
| Research and Development ExpenseUSD | 53,399,000Source | 24,903,000Source | 47,110,000Source | 87,552,000Source |